{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:41:53Z","timestamp":1792190513608,"version":"4.4.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100014565","name":"Bausch Health Companies Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014565","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03363-9","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:13:12Z","timestamp":1758615192000},"page":"5451-5467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["IL-17C as a Driver of Inflammation in Psoriasis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3302-5098","authenticated-orcid":false,"given":"George","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6892-6286","authenticated-orcid":false,"given":"April","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-1778","authenticated-orcid":false,"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-2280","authenticated-orcid":false,"given":"Abby","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"3363_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216095","volume":"24","author":"A-M Man","year":"2023","unstructured":"Man A-M, Or\u0103san MS, Hoteiuc O-A, Ol\u0103nescu-Vaida-Voevod M-C, Mocan T. Inflammation and psoriasis: a comprehensive review. Int J Mol Sci. 2023;24:16095. https:\/\/doi.org\/10.3390\/ijms242216095.","journal-title":"Int J Mol Sci"},{"key":"3363_CR2","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/jdv.16126","volume":"34","author":"F Lauffer","year":"2020","unstructured":"Lauffer F, Jargosch M, Baghin V, et al. IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema. J Eur Acad Dermatol Venereol. 2020;34:800\u20139. https:\/\/doi.org\/10.1111\/jdv.16126.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3363_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/ddg.14991","volume":"21","author":"F Lauffer","year":"2023","unstructured":"Lauffer F, Eyerich K. Eczematized psoriasis\u2014a frequent but often neglected variant of plaque psoriasis. J Dtsch Dermatol Ges. 2023;21:445\u201353. https:\/\/doi.org\/10.1111\/ddg.14991.","journal-title":"J Dtsch Dermatol Ges"},{"key":"3363_CR4","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/ni.2156","volume":"12","author":"V Ramirez-Carrozzi","year":"2011","unstructured":"Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol. 2011;12:1159\u201366. https:\/\/doi.org\/10.1038\/ni.2156.","journal-title":"Nat Immunol"},{"key":"3363_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.imlet.2016.05.001","volume":"178","author":"U Srenathan","year":"2016","unstructured":"Srenathan U, Steel K, Taams LS. IL-17+ CD8+ T\u00a0cells: differentiation, phenotype and role in inflammatory disease. Immunol Lett. 2016;178:20\u20136. https:\/\/doi.org\/10.1016\/j.imlet.2016.05.001.","journal-title":"Immunol Lett"},{"key":"3363_CR6","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.4049\/jimmunol.1201505","volume":"190","author":"A Johnston","year":"2013","unstructured":"Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190:2252\u201362. https:\/\/doi.org\/10.4049\/jimmunol.1201505.","journal-title":"J Immunol"},{"key":"3363_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","volume":"160","author":"C Johansen","year":"2009","unstructured":"Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160:319\u201324. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08902.x.","journal-title":"Br J Dermatol"},{"key":"3363_CR8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/bjd.20090","volume":"185","author":"MAX Tollenaere","year":"2021","unstructured":"Tollenaere MAX, Hebsgaard J, Ewald DA, et al. Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways. Br J Dermatol. 2021;185:585\u201394. https:\/\/doi.org\/10.1111\/bjd.20090.","journal-title":"Br J Dermatol"},{"key":"3363_CR9","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.jid.2018.01.036","volume":"138","author":"N Vandeghinste","year":"2018","unstructured":"Vandeghinste N, Klattig J, Jagerschmidt C, et al. Neutralization of IL-17C reduces skin inflammation in mouse models of psoriasis and atopic dermatitis. J Invest Dermatol. 2018;138:1555\u201363. https:\/\/doi.org\/10.1016\/j.jid.2018.01.036.","journal-title":"J Invest Dermatol"},{"key":"3363_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094983","volume":"23","author":"S Boonpethkaew","year":"2022","unstructured":"Boonpethkaew S, Meephansan J, Jumlongpim O, et al. Transcriptomic profiling of peripheral edge of lesions to elucidate the pathogenesis of psoriasis vulgaris. Int J Mol Sci. 2022;23:4983. https:\/\/doi.org\/10.3390\/ijms23094983.","journal-title":"Int J Mol Sci"},{"key":"3363_CR11","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.jid.2018.02.037","volume":"138","author":"E Guttman-Yassky","year":"2018","unstructured":"Guttman-Yassky E, Krueger JG. IL-17C: a unique epithelial cytokine with potential for targeting across the spectrum of atopic dermatitis and psoriasis. J Invest Dermatol. 2018;138:1467\u20139. https:\/\/doi.org\/10.1016\/j.jid.2018.02.037.","journal-title":"J Invest Dermatol"},{"key":"3363_CR12","unstructured":"Bimzelx [package insert]. Smyrna, GA: UCB, Inc; 2023."},{"key":"3363_CR13","unstructured":"Cosentyx [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023."},{"key":"3363_CR14","unstructured":"Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024."},{"key":"3363_CR15","doi-asserted-by":"publisher","first-page":"1186455","DOI":"10.3389\/fimmu.2023.1186455","volume":"14","author":"NC Brembilla","year":"2023","unstructured":"Brembilla NC, Boehncke W-H. Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Front Immunol. 2023;14:1186455. https:\/\/doi.org\/10.3389\/fimmu.2023.1186455.","journal-title":"Front Immunol"},{"key":"3363_CR16","unstructured":"Siliq [package insert]. Bridgewater, NJ: Bausch Health Companies Inc; 2024."},{"key":"3363_CR17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.immuni.2011.09.010","volume":"35","author":"SH Chang","year":"2011","unstructured":"Chang SH, Reynolds JM, Pappu BP, Chen G, Martinez GJ, Dong C. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity. 2011;35:611\u201321. https:\/\/doi.org\/10.1016\/j.immuni.2011.09.010.","journal-title":"Immunity"},{"key":"3363_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/jid.2010.340","volume":"131","author":"A Chiricozzi","year":"2011","unstructured":"Chiricozzi A, Guttman-Yassky E, Su\u00e1rez-Fari\u00f1as M, et al. Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131:677\u201387. https:\/\/doi.org\/10.1038\/jid.2010.340.","journal-title":"J Invest Dermatol"},{"key":"3363_CR19","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood-2002-05-1461","volume":"101","author":"M Numasaki","year":"2003","unstructured":"Numasaki M, Fukushi J-I, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101:2620\u20137. https:\/\/doi.org\/10.1182\/blood-2002-05-1461.","journal-title":"Blood"},{"key":"3363_CR20","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/ni.2155","volume":"12","author":"X Song","year":"2011","unstructured":"Song X, Zhu S, Shi P, et al. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol. 2011;12:1151\u20138. https:\/\/doi.org\/10.1038\/ni.2155.","journal-title":"Nat Immunol"},{"key":"3363_CR21","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372.","journal-title":"J Am Acad Dermatol"},{"key":"3363_CR22","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s13555-021-00573-1","volume":"11","author":"B Strober","year":"2021","unstructured":"Strober B, Pariser D, Deren-Lewis A, Dickerson TJ, Lebwohl M, Menter A. A survey of community dermatologists reveals the unnecessary impact of trial-and-error behavior on the psoriasis biologic treatment paradigm. Dermatol Ther (Heidelb). 2021;11:1851\u201360.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"3363_CR23","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jid.2019.12.013","volume":"140","author":"J Borowczyk","year":"2020","unstructured":"Borowczyk J, Buerger C, Tadjrischi N, et al. IL-17E (IL-25) and IL-17A differentially affect the functions of human keratinocytes. J Invest Dermatol. 2020;140:1379-89.e2. https:\/\/doi.org\/10.1016\/j.jid.2019.12.013.","journal-title":"J Invest Dermatol"},{"key":"3363_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/14712598.2020.1727439","volume":"20","author":"G Caldarola","year":"2020","unstructured":"Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020;20:665\u201372. https:\/\/doi.org\/10.1080\/14712598.2020.1727439.","journal-title":"Expert Opin Biol Ther"},{"key":"3363_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/discim\/kyad010","volume":"2","author":"AV Hipp","year":"2023","unstructured":"Hipp AV, Bengsch B, Globig AM. Friend or foe\u2014Tc17 cell generation and current evidence for their importance in human disease. Discovery Immunology. 2023;2:kyad010. https:\/\/doi.org\/10.1093\/discim\/kyad010.","journal-title":"Discovery Immunology"},{"key":"3363_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3389\/fimmu.2020.00341","volume":"11","author":"JF Nies","year":"2020","unstructured":"Nies JF, Panzer U. IL-17C\/IL-17RE: emergence of a unique axis in T(H)17 biology. Front Immunol. 2020;11:341. https:\/\/doi.org\/10.3389\/fimmu.2020.00341.","journal-title":"Front Immunol"},{"key":"3363_CR27","doi-asserted-by":"publisher","first-page":"6559","DOI":"10.4049\/jimmunol.167.11.6559","volume":"167","author":"G Pan","year":"2001","unstructured":"Pan G, French D, Mao W, et al. Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice. J Immunol. 2001;167:6559\u201367. https:\/\/doi.org\/10.4049\/jimmunol.167.11.6559.","journal-title":"J Immunol"},{"key":"3363_CR28","doi-asserted-by":"publisher","unstructured":"Vidal S, Puig L, Carrascosa-Carrillo JM, Gonz\u00e1lez-Cantero \u00c1, Ruiz-Carrascosa JC, Velasco-Pastor AM. From messengers to receptors in psoriasis: the role of IL-17RA in disease and treatment. Int J Mol Sci. 2021;22:6740. https:\/\/doi.org\/10.3390\/ijms22136740[Published correction appears in Int J Mol Sci. 2022;23:2649. https:\/\/doi.org\/10.3390\/ijms23052649].","DOI":"10.3390\/ijms22136740"},{"key":"3363_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ydbio.2006.08.065","volume":"300","author":"T Hibino","year":"2006","unstructured":"Hibino T, Loza-Coll M, Messier C, et al. The immune gene repertoire encoded in the purple sea urchin genome. Dev Biol. 2006;300:349\u201365. https:\/\/doi.org\/10.1016\/j.ydbio.2006.08.065.","journal-title":"Dev Biol"},{"key":"3363_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.692997","volume":"12","author":"A Saco","year":"2021","unstructured":"Saco A, Rey-Campos M, Rosani U, Novoa B, Figueras A. The evolution and diversity of interleukin-17\u00a0highlight an expansion in marine invertebrates and its conserved role in mucosal immunity. Front Immunol. 2021;12:692997. https:\/\/doi.org\/10.3389\/fimmu.2021.692997.","journal-title":"Front Immunol"},{"key":"3363_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615580","volume":"11","author":"A Saco","year":"2020","unstructured":"Saco A, Rey-Campos M, Novoa B, Figueras A. Transcriptomic response of mussel gills after a Vibrio splendidus infection demonstrates their role in the immune response. Front Immunol. 2020;11:615580. https:\/\/doi.org\/10.3389\/fimmu.2020.615580.","journal-title":"Front Immunol"},{"key":"3363_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","volume":"21","author":"JK Kolls","year":"2004","unstructured":"Kolls JK, Lind\u00e9n A. Interleukin-17 family members and inflammation. Immunity. 2004;21:467\u201376. https:\/\/doi.org\/10.1016\/j.immuni.2004.08.018.","journal-title":"Immunity"},{"key":"3363_CR33","doi-asserted-by":"publisher","first-page":"13447","DOI":"10.1074\/jbc.M700499200","volume":"282","author":"JF Wright","year":"2007","unstructured":"Wright JF, Guo Y, Quazi A, et al. Identification of an interleukin 17F\/17A heterodimer in activated human CD4+ T\u00a0cells. J Biol Chem. 2007;282:13447\u201355. https:\/\/doi.org\/10.1074\/jbc.M700499200.","journal-title":"J Biol Chem"},{"key":"3363_CR34","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1093\/emboj\/20.19.5332","volume":"20","author":"SG Hymowitz","year":"2001","unstructured":"Hymowitz SG, Filvaroff EH, Yin JP, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 2001;20:5332\u201341. https:\/\/doi.org\/10.1093\/emboj\/20.19.5332.","journal-title":"EMBO J"},{"key":"3363_CR35","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","volume":"183","author":"F Fossiez","year":"1996","unstructured":"Fossiez F, Djossou O, Chomarat P, et al. T\u00a0cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996;183:2593\u2013603. https:\/\/doi.org\/10.1084\/jem.183.6.2593.","journal-title":"J Exp Med"},{"key":"3363_CR36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1365-2613.2009.00669.x","volume":"90","author":"R Heidenreich","year":"2009","unstructured":"Heidenreich R, R\u00f6cken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol. 2009;90:232\u201348. https:\/\/doi.org\/10.1111\/j.1365-2613.2009.00669.x.","journal-title":"Int J Exp Pathol"},{"key":"3363_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.719562","volume":"12","author":"X Xu","year":"2021","unstructured":"Xu X, Prens E, Florencia E, et al. Interleukin-17A drives IL-19 and IL-24 expression in skin stromal cells regulating keratinocyte proliferation. Front Immunol. 2021;12:719562. https:\/\/doi.org\/10.3389\/fimmu.2021.719562.","journal-title":"Front Immunol"},{"key":"3363_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101937","volume":"9","author":"H Rabeony","year":"2014","unstructured":"Rabeony H, Petit-Paris I, Garnier J, et al. Inhibition of keratinocyte differentiation by the synergistic effect of IL-17A, IL-22, IL-1\u03b1, TNF\u03b1 and oncostatin M. PLoS ONE. 2014;9:e101937. https:\/\/doi.org\/10.1371\/journal.pone.0101937.","journal-title":"PLoS ONE"},{"key":"3363_CR39","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1084\/jem.20160581","volume":"214","author":"T Peng","year":"2017","unstructured":"Peng T, Chanthaphavong RS, Sun S, et al. Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation. J Exp Med. 2017;214:2315\u201329. https:\/\/doi.org\/10.1084\/jem.20160581.","journal-title":"J Exp Med"},{"key":"3363_CR40","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","volume":"192","author":"CB Russell","year":"2014","unstructured":"Russell CB, Rand H, Bigler J, et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol. 2014;192:3828\u201336. https:\/\/doi.org\/10.4049\/jimmunol.1301737.","journal-title":"J Immunol"},{"issue":"8","key":"3363_CR41","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.4049\/jimmunol.179.8.5462","volume":"179","author":"RE Kuestner","year":"2007","unstructured":"Kuestner RE, Taft DW, Haran A, et al. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol. 2007;179(8):5462\u201373.","journal-title":"J Immunol"},{"key":"3363_CR42","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","volume":"144","author":"JG Krueger","year":"2019","unstructured":"Krueger JG, Wharton KA Jr, Schlitt T, et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019;144:750\u201363. https:\/\/doi.org\/10.1016\/j.jaci.2019.04.029.","journal-title":"J Allergy Clin Immunol"},{"key":"3363_CR43","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3892\/etm.2021.9999","volume":"21","author":"Y Teng","year":"2021","unstructured":"Teng Y, Xie W, Tao X, et al. Infection-provoked psoriasis: induced or aggravated. Exp Ther Med. 2021;21:567. https:\/\/doi.org\/10.3892\/etm.2021.9999.","journal-title":"Exp Ther Med"},{"key":"3363_CR44","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80:1073\u2013113.","journal-title":"J Am Acad Dermatol"},{"key":"3363_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155641","volume":"146","author":"S Swedik","year":"2021","unstructured":"Swedik S, Madola A, Levine A. IL-17C in human mucosal immunity: more than just a middle child. Cytokine. 2021;146:155641.","journal-title":"Cytokine"},{"key":"3363_CR46","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/1744666X.2022.2116003","volume":"18","author":"H Bachelez","year":"2022","unstructured":"Bachelez H, Barker J, Burden AD, Navarini AA, Krueger JG. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Rev Clin Immunol. 2022;18:1033\u201347. https:\/\/doi.org\/10.1080\/1744666X.2022.2116003.","journal-title":"Expert Rev Clin Immunol"},{"key":"3363_CR47","first-page":"590","volume":"101","author":"W Frazier","year":"2020","unstructured":"Frazier W, Bhardwaj N. Atopic dermatitis: diagnosis and treatment. Am Fam Physician. 2020;101:590\u20138.","journal-title":"Am Fam Physician"},{"key":"3363_CR48","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bjd.20527","volume":"185","author":"PM Brunner","year":"2021","unstructured":"Brunner PM, Conrad C, Vender R, et al. Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab. Br J Dermatol. 2021;185:865\u20137. https:\/\/doi.org\/10.1111\/bjd.20527.","journal-title":"Br J Dermatol"},{"key":"3363_CR49","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/ced.15052","volume":"47","author":"M Megna","year":"2022","unstructured":"Megna M, Caiazzo G, Parisi M, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role? Clin Exp Dermatol. 2022;47:918\u201325. https:\/\/doi.org\/10.1111\/ced.15052.","journal-title":"Clin Exp Dermatol"},{"key":"3363_CR50","unstructured":"Data on file, Bausch Health Companies, Inc."},{"key":"3363_CR51","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1080\/09546634.2022.2062281","volume":"33","author":"F Messina","year":"2022","unstructured":"Messina F, Piaserico S. The dark side of the moon: the immune-mediated adverse events of IL-17A\/IL-17R inhibition. J Dermatolog Treat. 2022;33:2443\u201354. https:\/\/doi.org\/10.1080\/09546634.2022.2062281.","journal-title":"J Dermatolog Treat"},{"key":"3363_CR52","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CCID.S111019","volume":"10","author":"M Napolitano","year":"2017","unstructured":"Napolitano M, Megna M, Timoshchuk EA, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105\u201315. https:\/\/doi.org\/10.2147\/CCID.S111019.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"3363_CR53","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/bjd.18556","volume":"182","author":"K Navrazhina","year":"2020","unstructured":"Navrazhina K, Frew JW, Krueger JG. Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa. Br J Dermatol. 2020;182:1045\u20137. https:\/\/doi.org\/10.1111\/bjd.18556.","journal-title":"Br J Dermatol"},{"key":"3363_CR54","doi-asserted-by":"publisher","unstructured":"Novak-Bili\u0107 G, Vu\u010di\u0107 M, Japund\u017ei\u0107 I, Me\u0161trovi\u0107-\u0160tefekov J, Stani\u0107-Duktaj S, Lugovi\u0107-Mihi\u0107 L. Irritant and allergic contact dermatitis\u2014skin lesion characteristics. Acta Clin Croat. 2018;57:713\u201320. https:\/\/doi.org\/10.20471\/acc.2018.57.04.13.","DOI":"10.20471\/acc.2018.57.04.13"},{"key":"3363_CR55","first-page":"125","volume":"74","author":"RA Schwartz","year":"2006","unstructured":"Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician. 2006;74:125\u201330.","journal-title":"Am Fam Physician"},{"key":"3363_CR56","first-page":"14","volume":"2","author":"GK Kim","year":"2009","unstructured":"Kim GK. Seborrheic dermatitis and Malassezia species: how are they related? J Clin Aesthet Dermatol. 2009;2:14\u20137.","journal-title":"J Clin Aesthet Dermatol"},{"key":"3363_CR57","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/infdis\/jiab194","volume":"223","author":"H Miyachi","year":"2021","unstructured":"Miyachi H, Wakabayashi S, Sugihira T, et al. Keratinocyte IL-36 receptor\/MyD88 signaling mediates malassezia-induced IL-17-dependent skin inflammation. J Infect Dis. 2021;223:1753\u201365. https:\/\/doi.org\/10.1093\/infdis\/jiab194.","journal-title":"J Infect Dis"},{"key":"3363_CR58","unstructured":"Skyrizi [package insert]. North Chicago, IL: AbbVie Inc; 2024."},{"key":"3363_CR59","unstructured":"Ilumya [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; 2022."},{"key":"3363_CR60","unstructured":"EnbreL [package insert]. Thousand Oaks, CA: Amgen; 2023."},{"key":"3363_CR61","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, et al. A prospective phase\u00a0III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273\u201386. https:\/\/doi.org\/10.1111\/bjd.14493.","journal-title":"Br J Dermatol"},{"key":"3363_CR62","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, et al. Phase\u00a03 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1503824.","journal-title":"N Engl J Med"},{"key":"3363_CR63","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase\u00a03 trial. Lancet. 2021;397:487\u201398.","journal-title":"Lancet"},{"issue":"4","key":"3363_CR64","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis\u2013results of two phase\u00a03 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"9993","key":"3363_CR65","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase\u00a03 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"key":"3363_CR66","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jaad.2019.05.007","volume":"81","author":"G Kimmel","year":"2019","unstructured":"Kimmel G, Chima M, Kim HJ, et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol. 2019;81:857\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.007.","journal-title":"J Am Acad Dermatol"},{"key":"3363_CR67","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaad.2020.11.013","volume":"84","author":"J Yeung","year":"2021","unstructured":"Yeung J, Vender R, Turchin I, et al. Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors. J Am Acad Dermatol. 2021;84:1169\u201371. https:\/\/doi.org\/10.1016\/j.jaad.2020.11.013.","journal-title":"J Am Acad Dermatol"},{"key":"3363_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15106","volume":"34","author":"N Loft","year":"2021","unstructured":"Loft N, Bregnh\u00f8j A, Fage S, et al. Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis. Dermatol Ther. 2021;34:e15106. https:\/\/doi.org\/10.1111\/dth.15106.","journal-title":"Dermatol Ther"},{"key":"3363_CR69","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaad.2024.01.025","volume":"90","author":"K Papp","year":"2024","unstructured":"Papp K, Prajapati VH, Maari C, Legault M, Barakat M, Vender R. Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: a phase\u00a04, multicenter, open-label study. J Am Acad Dermatol. 2024;90:1254\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2024.01.025.","journal-title":"J Am Acad Dermatol"},{"key":"3363_CR70","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00403-019-01907-y","volume":"311","author":"I Gasslitter","year":"2019","unstructured":"Gasslitter I, Kirsten N, Augustin M, et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res. 2019;311:421\u20134. https:\/\/doi.org\/10.1007\/s00403-019-01907-y.","journal-title":"Arch Dermatol Res"},{"key":"3363_CR71","unstructured":"Papp K, Lebwohl M, Armstrong A, Desai S, Legault M, Jacobson A. Efficacy and safety of brodalumab in patients with moderate-to-severe plaque psoriasis and inadequate response to prior biologics. Poster presented at: Fall Clinical Dermatology Conference for Dermatologists; October 19\u201322, 2023; Las Vegas, NV."},{"key":"3363_CR72","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1080\/09546634.2020.1716932","volume":"32","author":"C Kromer","year":"2021","unstructured":"Kromer C, Wilsmann-Theis D, Gerdes S, et al. Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker\u2014a retrospective multicenter study. J Dermatolog Treat. 2021;32:878\u201382. https:\/\/doi.org\/10.1080\/09546634.2020.1716932.","journal-title":"J Dermatolog Treat"},{"key":"3363_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122807","volume":"10","author":"HR Conti","year":"2015","unstructured":"Conti HR, Whibley N, Coleman BM, Garg AV, Jaycox JR, Gaffen SL. Signaling through IL-17C\/IL-17RE is dispensable for immunity to systemic, oral and cutaneous candidiasis. PLoS ONE. 2015;10:e0122807.","journal-title":"PLoS ONE"},{"key":"3363_CR74","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ddg.15251","volume":"22","author":"L Mastorino","year":"2024","unstructured":"Mastorino L, Dapavo P, Susca S, et al. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. J Dtsch Dermatol Ges. 2024;22:34\u201342. https:\/\/doi.org\/10.1111\/ddg.15251.","journal-title":"J Dtsch Dermatol Ges"},{"key":"3363_CR75","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjd.14702","volume":"176","author":"K Yamasaki","year":"2017","unstructured":"Yamasaki K, Nakagawa H, Kubo Y, Ootaki K. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176:741\u201351. https:\/\/doi.org\/10.1111\/bjd.14702.","journal-title":"Br J Dermatol"},{"key":"3363_CR76","unstructured":"Lumicef [package insert]. Taiwan: Kyowa Hakko Kirin Taiwan Co, Ltd; 2018."},{"key":"3363_CR77","unstructured":"Kyowa Kirin received partial change approval of Lumicef\u00ae for palmoplantar pustulosis in Japan [news release]. Kyowa Kirin. https:\/\/www.kyowakirin.com\/media_center\/news_releases\/2023\/e20230823_01.html. Accessed Mar 31, 2025."},{"key":"3363_CR78","unstructured":"Public Pharmaceutical Regulatory Infomation. Lumicef subcutaneous injection 210 Mg syringe [details of medicinal product]. Thailand Food and Drug Administration, Ministry of Public Health. https:\/\/pertento.fda.moph.go.th\/FDA_INFORMATION_DRUG\/Home\/Phar_Product_Inform_Page?Newcode=U1DR1C1072611505111C. Accessed Jul 17, 2024."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03363-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03363-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03363-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:02:29Z","timestamp":1762030949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03363-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":78,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3363"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03363-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"George Han is an Editorial Board member of\n                      Advances in Therapy\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions; is or has been an investigator for Athenex, Boehringer Ingelheim, Bond Avillion, Bristol-Myers Squibb, Celgene, Janssen, Lilly, MC2, Novartis, PellePharm, Pfizer, and UCB and is a consultant, advisor, or speaker for AbbVie, Boehringer Ingelheim, Dermtech, Incyte, Janssen, LEO Pharma, Lilly, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Sun Pharmaceutical Industries, and UCB. April Armstrong has served as a research investigator, scientific advisor, or speaker for AbbVie, Almirall, Amgen, Arcutis, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, BMS, Dermavant, Dermira, EPI, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharmaceutical Industries, Takeda, and UCB. James G. Krueger reports consulting fees and research support paid to his institution by Abbott Laboratories, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, DBV Technologies, Dermira, EMD Serono, IDEA Pharma, Janssen, LEO Pharma, Lilly, Merck & Co, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Sun Pharmaceutical Industries, Valeant Pharmaceuticals, and Vitae Pharmaceuticals. Abby Jacobson is an employee of Bausch Health Companies Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}